Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 360 entries
View as:

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT02914314 Org: User:
Start: 02/20/17 End: 04/25/23 Due: 04/25/24

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03663114 Org: User:
Start: 07/02/18 End: 02/20/20 Due: 02/20/21

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03245450 Org: User:
Start: 03/05/18 End: 05/17/21 Due: 05/17/22

A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.

Phase: N/A Priority: Normal
NCT ID: NCT00327392 Org: User:
Start: 05/31/06 End: 12/31/07 Due: 12/31/08

Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations

Phase: N/A Priority: Normal
NCT ID: NCT01673880 Org: User:
Start: 08/31/12 End: 12/31/12 Due: 12/31/13

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Phase: N/A Priority: Normal
NCT ID: NCT04144140 Org: User:
Start: 02/24/20 End: 07/26/22 Due: 07/26/23

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Phase: N/A Priority: Normal
NCT ID: NCT00699582 Org: User:
Start: 05/31/08 End: 01/31/11 Due: 01/31/12

A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT03603639 Org: User:
Start: 07/27/18 End: 02/14/19 Due: 02/14/20

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00478205 Org: User:
Start: 06/30/07 End: - Due: -

Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT00358644 Org: User:
Start: 03/31/05 End: 12/31/08 Due: 12/31/09

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Phase: N/A Priority: Normal
NCT ID: NCT00246090 Org: User:
Start: 10/31/05 End: 09/30/07 Due: 09/30/08

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

Phase: N/A Priority: Normal
NCT ID: NCT00165737 Org: User:
Start: 03/31/03 End: 06/30/06 Due: 06/30/07

An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy

Phase: N/A Priority: Normal
NCT ID: NCT00261599 Org: User:
Start: 03/31/06 End: 10/31/06 Due: 10/31/07

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02046213 Org: User:
Start: 02/28/14 End: 05/31/14 Due: 05/31/15

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Phase: N/A Priority: Normal
NCT ID: NCT00211198 Org: User:
Start: 05/31/01 End: 01/31/06 Due: 01/31/07

Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver

Phase: N/A Priority: Normal
NCT ID: NCT00280410 Org: User:
Start: 02/28/06 End: - Due: -

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02039076 Org: User:
Start: 12/31/13 End: 09/30/14 Due: 09/30/15

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Phase: N/A Priority: Normal
NCT ID: NCT01525394 Org: User:
Start: 12/31/10 End: - Due: -

Safety and Efficacy of APD356 in the Treatment of Obesity

Phase: N/A Priority: Normal
NCT ID: NCT00104507 Org: User:
Start: 12/31/04 End: 05/31/05 Due: 05/31/06

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase: N/A Priority: Normal
NCT ID: NCT04300556 Org: User:
Start: 08/06/20 End: 12/31/24 Due: 12/31/25

A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01261156 Org: User:
Start: 10/31/10 End: - Due: -

Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01396577 Org: User:
Start: 12/31/10 End: 04/30/11 Due: 04/30/12

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01269346 Org: User:
Start: 12/31/10 End: 05/31/16 Due: 05/31/17

An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00121732 Org: User:
Start: 07/31/05 End: 10/31/09 Due: 10/31/10

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02723630 Org: User:
Start: 07/31/13 End: 08/31/13 Due: 08/31/14